Antioxidant therapies in traumatic brain and spinal cord injury

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 5, 2012, Pages 675-684

  Bains, Mona ^a   Hall, Edward D ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Antioxidant; Lipid peroxidation; Oxidative damage; Reactive oxygen species; Spinal cord injury; Traumatic brain injury

Indexed keywords

2 [[4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL]METHYL] 3,4 DIHYDRO 2,5,7,8 TETRAMETHYL 2H 1 BENZOPYRAN 6 OL; ANTIOXIDANT; CYCLIC GMP; DEXAMETHASONE; DEXANABINOL; GLUTATHIONE S TRANSFERASE ALPHA1; GLUTATHIONE TRANSFERASE ALPHA; HEME OXYGENASE 1; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MALONALDEHYDE; MELATONIN; MESSENGER RNA; METHYLPREDNISOLONE; NAD(P)H:QUINONEREDUCTASE 1; PEGORGOTEIN; PENICILLAMINE; PEROXYNITRITE; PHENELZINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESVERATROL; SULFORAPHANE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TEMPOL; TIRILAZAD; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; BLOOD BRAIN BARRIER; CALCIUM CELL LEVEL; CELL DAMAGE; CELL PROTECTION; COMPARATIVE EFFECTIVENESS; CORTICOSTEROID THERAPY; CYTOSKELETON; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; ENZYME ACTIVATION; GASTROINTESTINAL HEMORRHAGE; HISTORY OF MEDICINE; HUMAN; HYPERGLYCEMIA; LIPID PEROXIDATION; LOW DRUG DOSE; MITOCHONDRION; MULTICENTER STUDY (TOPIC); NERVE DEGENERATION; NEUROPROTECTION; NITRATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PH; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPINAL CORD INJURY; SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN INJURY; UPREGULATION; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

ANTIOXIDANTS; BRAIN INJURIES; HUMANS; LIPID PEROXIDATION; REACTIVE OXYGEN SPECIES; SPINAL CORD INJURIES;

EID: 84858151224     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.10.017     Document Type: Review

References (136)

1. Beckman J.S. Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol. 1996, 9:836-844.
2. Radi R. Peroxynitrite reactions and diffusion in biology. Chem. Res. Toxicol. 1998, 11:720-721.
3. Hall E.D., Oostveen J.A., Andrus P.K., Anderson D.K., Thomas C.E. Immunocytochemical method for investigating in vivo neuronal oxygen radical-induced lipid peroxidation. J. Neurosci. Methods 1997, 76:115-122.
4. Deng Y., Thompson B.M., Gao X., Hall E.D. Temporal relationship of peroxynitrite-induced oxidative damage, calpain-mediated cytoskeletal degradation and neurodegeneration after traumatic brain injury. Exp. Neurol. 2007, 205:154-165.
5. Gutteridge J.M. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin. Chem. 1995, 41:1819-1828.
6. Rohn T.T., Hinds T.R., Vincenzi F.F. Ion transport ATPases as targets for free radical damage. Protection by an aminosteroid of the Ca2+ pump ATPase and Na+/K+ pump ATPase of human red blood cell membranes. Biochem. Pharmacol. 1993, 46:525-534.
7. Rohn T.T., Hinds T.R., Vincenzi F.F. Inhibition of Ca2+-pump ATPase and the Na+/K+-pump ATPase by iron-generated free radicals. Protection by 6,7-dimethyl-2,4-DI-1- pyrrolidinyl-7H-pyrrolo[2,3-d] pyrimidine sulfate (U-89843D), a potent, novel, antioxidant/free radical scavenger. Biochem. Pharmacol. 1996, 51:471-476.
8. Bringold U., Ghafourifar P., Richter C. Peroxynitrite formed by mitochondrial NO synthase promotes mitochondrial Ca2+ release. Free Radic. Biol. Med. 2000, 29:343-348.
9. Sullivan P.G., Krishnamurthy S., Patel S.P., Pandya J.D., Rabchevsky A.G. Temporal characterization of mitochondrial bioenergetics after spinal cord injury. J. Neurotrauma 2007, 24:991-999.
10. Carrico K.M., Vaishnav R., Hall E.D. Temporal and spatial dynamics of peroxynitrite-induced oxidative damage after spinal cord contusion injury. J. Neurotrauma 2009, 26:1369-1378.
11. Zhang J.R., Scherch H.M., Hall E.D. Direct measurement of lipid hydroperoxides in iron-dependent spinal neuronal injury. J. Neurochem. 1996, 66:355-361.
12. Monyer H., Hartley D.M., Choi D.W. 21-Aminosteroids attenuate excitotoxic neuronal injury in cortical cell cultures. Neuron 1990, 5:121-126.
13. Hall E.D., Wolf D.L. A pharmacological analysis of the pathophysiological mechanisms of posttraumatic spinal cord ischemia. J. Neurosurg. 1986, 64:951-961.
14. Kontos H.A., Povlishock J.T. Oxygen radicals in brain injury. Cent. Nerv. Syst. Trauma 1986, 3:257-263.
15. Kontos H.A., Wei E.P. Superoxide production in experimental brain injury. J. Neurosurg. 1986, 64:803-807.
16. Hall E.D., Andrus P.K., Yonkers P.A. Brain hydroxyl radical generation in acute experimental head injury. J. Neurochem. 1993, 60:588-594.
17. Hall E.D., Andrus P.K., Yonkers P.A., Smith S.L., Zhang J.R., Taylor B.M., Sun F.F. Generation and detection of hydroxyl radical following experimental head injury. Ann. N. Y. Acad. Sci. 1994, 738:15-24.
18. Smith S.L., Andrus P.K., Zhang J.R., Hall E.D. Direct measurement of hydroxyl radicals, lipid peroxidation, and blood-brain barrier disruption following unilateral cortical impact head injury in the rat. J. Neurotrauma 1994, 11:393-404.
19. Cobbs C.S., Fenoy A., Bredt D.S., Noble L.J. Expression of nitric oxide synthase in the cerebral microvasculature after traumatic brain injury in the rat. Brain Res. 1997, 751:336-338.
20. Rao V.L., Dogan A., Bowen K.K., Dempsey R.J. Traumatic injury to rat brain upregulates neuronal nitric oxide synthase expression and L-[3H]nitroarginine binding. J. Neurotrauma 1999, 16:865-877.
21. Gahm C., Holmin S., Mathiesen T. Temporal profiles and cellular sources of three nitric oxide synthase isoforms in the brain after experimental contusion. Neurosurgery 2000, 46:169-177.
22. Mesenge C., Charriaut-Marlangue C., Verrecchia C., Allix M., Boulu R.R., Plotkine M. Reduction of tyrosine nitration after N(omega)-nitro-L-arginine-methylester treatment of mice with traumatic brain injury. Eur. J. Pharmacol. 1998, 353:53-57.
23. Hall E.D., Detloff M.R., Johnson K., Kupina N.C. Peroxynitrite-mediated protein nitration and lipid peroxidation in a mouse model of traumatic brain injury. J. Neurotrauma 2004, 21:9-20.
24. Bayir H., Kagan V.E., Borisenko G.G., Tyurina Y.Y., Janesko K.L., Vagni V.A., Billiar T.R., Williams D.L., Kochanek P.M. Enhanced oxidative stress in iNOS-deficient mice after traumatic brain injury: support for a neuroprotective role of iNOS. J. Cereb. Blood Flow Metab. 2005, 25:673-684.
25. Hall E.D., McCall J.M., Means E.D. Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv. Pharmacol. 1994, 28:221-268.
26. Awasthi D., Church D.F., Torbati D., Carey M.E., Pryor W.A. Oxidative stress following traumatic brain injury in rats. Surg. Neurol. 1997, 47:575-581.
27. discussion 581-572.
28. Mori T., Kawamata T., Katayama Y., Maeda T., Aoyama N., Kikuchi T., Uwahodo Y. Antioxidant, OPC-14117, attenuates edema formation, and subsequent tissue damage following cortical contusion in rats. Acta Neurochir. 1998, (Suppl. 71):120-122.
29. Marklund N., Clausen F., Lewen A., Hovda D.A., Olsson Y., Hillered L. alpha-Phenyl-tert-N-butyl nitrone (PBN) improves functional and morphological outcome after cortical contusion injury in the rat. Acta Neurochir. (Wien) 2001, 143:73-81.
30. Liu D., Sybert T.E., Qian H., Liu J. Superoxide production after spinal injury detected by microperfusion of cytochrome c. Free Radic. Biol. Med. 1998, 25:298-304.
31. Liu J.B., Tang T.S., Xiao D.S. Changes of free iron contents and its correlation with lipid peroxidation after experimental spinal cord injury. Chin. J. Traumatol. 2004, 7:229-232.
32. Bao F., Liu D. Hydroxyl radicals generated in the rat spinal cord at the level produced by impact injury induce cell death by necrosis and apoptosis: protection by a metalloporphyrin. Neuroscience 2004, 126:285-295.
33. Seligman M.L., Flamm E.S., Goldstein B.D., Poser R.G., Demopoulos H.B., Ransohoff J. Spectrofluorescent detection of malonaldehyde as a measure of lipid free radical damage in response to ethanol potentiation of spinal cord trauma. Lipids 1977, 12:945-950.
34. Hall E.D., Braughler J.M. Effects of intravenous methylprednisolone on spinal cord lipid peroxidation and Na+ + K+)-ATPase activity. Dose-response analysis during 1st hour after contusion injury in the cat. J. Neurosurg. 1982, 57:247-253.
35. Qian H., Liu D. The time course of malondialdehyde production following impact injury to rat spinal cord as measured by microdialysis and high pressure liquid chromatography. Neurochem. Res. 1997, 22:1231-1236.
36. Xiong Y., Rabchevsky A.G., Hall E.D. Role of peroxynitrite in secondary oxidative damage after spinal cord injury. J. Neurochem. 2007, 100:639-649.
37. Baldwin S.A., Broderick R., Osbourne D., Waeg G., Blades D.A., Scheff S.W. The presence of 4-hydroxynonenal/protein complex as an indicator of oxidative stress after experimental spinal cord contusion in a rat model. J. Neurosurg. 1998, 88:874-883.
38. Springer J.E., Azbill R.D., Mark R.J., Begley J.G., Waeg G., Mattson M.P. 4-hydroxynonenal, a lipid peroxidation product, rapidly accumulates following traumatic spinal cord injury and inhibits glutamate uptake. J. Neurochem. 1997, 68:2469-2476.
39. Luo J., Uchida K., Shi R. Accumulation of acrolein-protein adducts after traumatic spinal cord injury. Neurochem. Res. 2005, 30:291-295.
40. Hamann K., Durkes A., Ouyang H., Uchida K., Pond A., Shi R. Critical role of acrolein in secondary injury following ex vivo spinal cord trauma. J. Neurochem. 2008, 107:712-721.
41. Bao F., Liu D. Peroxynitrite generated in the rat spinal cord induces apoptotic cell death and activates caspase-3. Neuroscience 2003, 116:59-70.
42. Bao F., DeWitt D.S., Prough D.S., Liu D. Peroxynitrite generated in the rat spinal cord induces oxidation and nitration of proteins: reduction by Mn (III) tetrakis (4-benzoic acid) porphyrin. J. Neurosci. Res. 2003, 71:220-227.
43. Bao F., Liu D. Peroxynitrite generated in the rat spinal cord induces neuron death and neurological deficits. Neuroscience 2002, 115:839-849.
44. Liu D., Bao F., Prough D.S., Dewitt D.S. Peroxynitrite generated at the level produced by spinal cord injury induces peroxidation of membrane phospholipids in normal rat cord: reduction by a metalloporphyrin. J. Neurotrauma 2005, 22:1123-1133.
45. Steroids and Brain Edema 1972, Springer-Verlag Inc., Berlin. H.J. Reulen, K. Schurmann (Eds.).
46. Hall E.D., Baker T., Riker W.F. Glucocorticoid effects on spinal cord function. J. Pharmacol. Exp. Ther. 1978, 206:361-370.
47. Hall E.D., Baker T. Further studies of glucocorticoid effects on spinal cord function: single and repetitive monosynaptic transmission and apparent Ia afferent transmitter turnover. J. Pharmacol. Exp. Ther. 1979, 210:112-115.
48. Hall E.D., Braughler J.M. Glucocorticoid mechanisms in acute spinal cord injury: a review and therapeutic rationale. Surg. Neurol. 1982, 18:320-327.
49. Hall E.D., Braughler J.M. Acute effects of intravenous glucocorticoid pretreatment on the in vitro peroxidation of cat spinal cord tissue. Exp. Neurol. 1981, 73:321-324.
50. Hall E.D., Wolf D.L., Braughler J.M. Effects of a single large dose of methylprednisolone sodium succinate on experimental posttraumatic spinal cord ischemia. Dose-response and time-action analysis. J. Neurosurg. 1984, 61:124-130.
51. Young W., Flamm E.S. Effect of high-dose corticosteroid therapy on blood flow, evoked potentials, and extracellular calcium in experimental spinal injury. J. Neurosurg. 1982, 57:667-673.
52. Anderson D.K., Means E.D., Waters T.R., Green E.S. Microvascular perfusion and metabolism in injured spinal cord after methylprednisolone treatment. J. Neurosurg. 1982, 56:106-113.
53. Braughler J.M., Hall E.D. Correlation of methylprednisolone levels in cat spinal cord with its effects on (Na+ + K+)-ATPase, lipid peroxidation, and alpha motor neuron function. J. Neurosurg. 1982, 56:838-844.
54. Hall E.D. The neuroprotective pharmacology of methylprednisolone. J. Neurosurg. 1992, 76:13-22.
55. Hall E.D., McCall J.M., Chase R.L., Yonkers P.A., Braughler J.M. A nonglucocorticoid steroid analog of methylprednisolone duplicates its high-dose pharmacology in models of central nervous system trauma and neuronal membrane damage. J. Pharmacol. Exp. Ther. 1987, 242:137-142.
56. Hall E.D., Springer J.E. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 2004, 1:80-100.
57. Bracken M.B., Collins W.F., Freeman D.F., Shepard M.J., Wagner F.W., Silten R.M., Hellenbrand K.G., Ransohoff J., Hunt W.E., Perot P.L., et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA 1984, 251:45-52.
58. Bracken M.B., Shepard M.J., Hellenbrand K.G., Collins W.F., Leo L.S., Freeman D.F., Wagner F.C., Flamm E.S., Eisenberg H.M., Goodman J.H., et al. Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J. Neurosurg. 1985, 63:704-713.
59. Bracken M.B., Shepard M.J., Collins W.F., Holford T.R., Young W., Baskin D.S., Eisenberg H.M., Flamm E., Leo-Summers L., Maroon J., et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N. Engl. J. Med. 1990, 322:1405-1411.
60. Bracken M.B., Shepard M.J., Collins W.F., Holford T.R., Baskin D.S., Eisenberg H.M., Flamm E., Leo-Summers L., Maroon J.C., Marshall L.F., et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J. Neurosurg. 1992, 76:23-31.
61. Bracken M.B., Holford T.R. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2. J. Neurosurg. 1993, 79:500-507.
62. Otani K. Beneficial effect of methylprednisolone sodium succinate in the treatment of acute spinal cord injury. Sekitsui Sekizui 1994, 7:633-647.
63. Petitjean M.E., Pointillart V., Dixmerias F., Wiart L., Sztark F., Lassie P., Thicoipe M., Dabadie P. Medical treatment of spinal cord injury in the acute stage. Ann. Fr. Anesth. Reanim. 1998, 17:114-122.
64. Hall E.D., Braughler J.M., McCall J.M. New pharmacological treatment of acute spinal cord trauma. J. Neurotrauma 1988, 5:81-89.
65. Anderson D.K., Braughler J.M., Hall E.D., Waters T.R., McCall J.M., Means E.D. Effects of treatment with U-74006F on neurological outcome following experimental spinal cord injury. J. Neurosurg. 1988, 69:562-567.
66. Anderson D.K., Hall E.D., Braughler J.M., McCall J.M., Means E.D. Effect of delayed administration of U74006F (tirilazad mesylate) on recovery of locomotor function after experimental spinal cord injury. J. Neurotrauma 1991, 8:187-192.
67. Bracken M.B., Shepard M.J., Holford T.R., Leo-Summers L., Aldrich E.F., Fazl M., Fehlings M., Herr D.L., Hitchon P.W., Marshall L.F., Nockels R.P., Pascale V., Perot P.L., Piepmeier J., Sonntag V.K., Wagner F., Wilberger J.E., Winn H.R., Young W. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997, 277:1597-1604.
68. Bracken M.B., Shepard M.J., Holford T.R., Leo-Summers L., Aldrich E.F., Fazl M., Fehlings M.G., Herr D.L., Hitchon P.W., Marshall L.F., Nockels R.P., Pascale V., Perot P.L., Piepmeier J., Sonntag V.K., Wagner F., Wilberger J.E., Winn H.R., Young W. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J. Neurosurg. 1998, 89:699-706.
69. Hurlbert R.J. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J. Neurosurg. 2000, 93:1-7.
70. Short D.J., El Masry W.S., Jones P.W. High dose methylprednisolone in the management of acute spinal cord injury - a systematic review from a clinical perspective. Spinal Cord 2000, 38:273-286.
71. Coleman W.P., Benzel D., Cahill D.W., Ducker T., Geisler F., Green B., Gropper M.R., Goffin J., Madsen P.W., Maiman D.J., Ondra S.L., Rosner M., Sasso R.C., Trost G.R., Zeidman S. A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury. J. Spinal Disord. 2000, 13:185-199.
72. Fehlings M.G. Editorial: recommendations regarding the use of methylprednisolone in acute spinal cord injury: making sense out of the controversy. Spine (Phila Pa 1976) 2001, 26:S56-S57.
73. Fehlings M.G. Summary statement: the use of methylprednisolone in acute spinal cord injury. Spine (Phila Pa 1976) 2001, 26:S55.
74. Fawcett J.W., Curt A., Steeves J.D., Coleman W.P., Tuszynski M.H., Lammertse D., Bartlett P.F., Blight A.R., Dietz V., Ditunno J., Dobkin B.H., Havton L.A., Ellaway P.H., Fehlings M.G., Privat A., Grossman R., Guest J.D., Kleitman N., Nakamura M., Gaviria M., Short D. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007, 45:190-205.
75. Steeves J.D., Lammertse D., Curt A., Fawcett J.W., Tuszynski M.H., Ditunno J.F., Ellaway P.H., Fehlings M.G., Guest J.D., Kleitman N., Bartlett P.F., Blight A.R., Dietz V., Dobkin B.H., Grossman R., Short D., Nakamura M., Coleman W.P., Gaviria M., Privat A. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 2007, 45:206-221.
76. Tuszynski M.H., Steeves J.D., Fawcett J.W., Lammertse D., Kalichman M., Rask C., Curt A., Ditunno J.F., Fehlings M.G., Guest J.D., Ellaway P.H., Kleitman N., Bartlett P.F., Blight A.R., Dietz V., Dobkin B.H., Grossman R., Privat A. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics. Spinal Cord 2007, 45:222-231.
77. Lammertse D., Tuszynski M.H., Steeves J.D., Curt A., Fawcett J.W., Rask C., Ditunno J.F., Fehlings M.G., Guest J.D., Ellaway P.H., Kleitman N., Blight A.R., Dobkin B.H., Grossman R., Katoh H., Privat A., Kalichman M. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design. Spinal Cord 2007, 45:232-242.
78. Muizelaar J.P., Marmarou A., Young H.F., Choi S.C., Wolf A., Schneider R.L., Kontos H.A. Improving the outcome of severe head injury with the oxygen radical scavenger polyethylene glycol-conjugated superoxide dismutase: a phase II trial. J. Neurosurg. 1993, 78:375-382.
79. Muizelaar J.P., Kupiec J.W., Rapp L.A. PEG-SOD after head injury. J. Neurosurg. 1995, 83:942.
80. Marshall L.F., Maas A.I., Marshall S.B., Bricolo A., Fearnside M., Iannotti F., Klauber M.R., Lagarrigue J., Lobato R., Persson L., Pickard J.D., Piek J., Servadei F., Wellis G.N., Morris G.F., Means E.D., Musch B. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J. Neurosurg. 1998, 89:519-525.
81. Farin A., Deutsch R., Biegon A., Marshall L.F. Sex-related differences in patients with severe head injury: greater susceptibility to brain swelling in female patients 50 years of age and younger. J. Neurosurg. 2003, 98:32-36.
82. Farin A., Marshall L.F. Lessons from epidemiologic studies in clinical trials of traumatic brain injury. Acta. Neurochir. 2004, (Suppl. 89):101-107.
83. Menon D.K. Unique challenges in clinical trials in traumatic brain injury. Crit. Care Med. 2009, 37:S129-S135.
84. Hall E.D., Vaishnav R.A., Mustafa A.G. Antioxidant therapies for traumatic brain injury. Neurotherapeutics 2010, 7:51-61.
85. Hall E.D. Antioxidant therapies for acute spinal cord injury. Neurotherapeutics 2011, 8:152-167.
86. Mustafa A.G., Singh I.N., Wang J., Carrico K.M., Hall E.D. Mitochondrial protection after traumatic brain injury by scavenging lipid peroxyl radicals. J. Neurochem. 2010, 114:271-280.
87. Mustafa A.G., Wang J.A., Carrico K.M., Hall E.D. Pharmacological inhibition of lipid peroxidation attenuates calpain-mediated cytoskeletal degradation after traumatic brain injury. J. Neurochem. 2011, 117:579-588.
88. Reiter R.J., Carneiro R.C., Oh C.S. Melatonin in relation to cellular antioxidative defense mechanisms. Horm. Metab. Res. 1997, 29:363-372.
89. Longoni B., Salgo M.G., Pryor W.A., Marchiafava P.L. Effects of melatonin on lipid peroxidation induced by oxygen radicals. Life Sci. 1998, 62:853-859.
90. Zhang H., Squadrito G.L., Pryor W.A. The reaction of melatonin with peroxynitrite: formation of melatonin radical cation and absence of stable nitrated products. Biochem. Biophys. Res. Commun. 1998, 251:83-87.
91. Zhang H., Squadrito G.L., Uppu R., Pryor W.A. Reaction of peroxynitrite with melatonin: a mechanistic study. Chem. Res. Toxicol. 1999, 12:526-534.
92. Fujimoto T., Nakamura T., Ikeda T., Takagi K. Potent protective effects of melatonin on experimental spinal cord injury. Spine (Phila Pa 1976) 2000, 25:769-775.
93. Kaptanoglu E., Tuncel M., Palaoglu S., Konan A., Demirpence E., Kilinc K. Comparison of the effects of melatonin and methylprednisolone in experimental spinal cord injury. J. Neurosurg. 2000, 93:77-84.
94. Gul S., Celik S.E., Kalayci M., Tasyurekli M., Cokar N., Bilge T. Dose-dependent neuroprotective effects of melatonin on experimental spinal cord injury in rats. Surg. Neurol. 2005, 64:355-361.
95. Samantaray S., Das A., Thakore N.P., Matzelle D.D., Reiter R.J., Ray S.K., Banik N.L. Therapeutic potential of melatonin in traumatic central nervous system injury. J. Pineal. Res. 2009, 47:134-142.
96. Genovese T., Mazzon E., Crisafulli C., Esposito E., Di Paola R., Muia C., Di Bella P., Bramanti P., Cuzzocrea S. Effects of combination of melatonin and dexamethasone on secondary injury in an experimental mice model of spinal cord trauma. J. Pineal. Res. 2007, 43:140-153.
97. Park K., Lee Y., Park S., Lee S., Hong Y., Kil Lee S. Synergistic effect of melatonin on exercise-induced neuronal reconstruction and functional recovery in a spinal cord injury animal model. J. Pineal. Res. 2010, 48:270-281.
98. Ozdemir D., Tugyan K., Uysal N., Sonmez U., Sonmez A., Acikgoz O., Ozdemir N., Duman M., Ozkan H. Protective effect of melatonin against head trauma-induced hippocampal damage and spatial memory deficits in immature rats. Neurosci. Lett. 2005, 385:234-239.
99. Ozdemir D., Uysal N., Gonenc S., Acikgoz O., Sonmez A., Topcu A., Ozdemir N., Duman M., Semin I., Ozkan H. Effect of melatonin on brain oxidative damage induced by traumatic brain injury in immature rats. Physiol. Res. 2005, 54:631-637.
100. Beni S.M., Kohen R., Reiter R.J., Tan D.X., Shohami E. Melatonin-induced neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late-phase activation of NF-kappaB and AP-1. FASEB J. 2004, 18:149-151.
101. Kelso M.L., Scheff N.N., Scheff S.W., Pauly J.R. Melatonin and minocycline for combinatorial therapy to improve functional and histopathological deficits following traumatic brain injury. Neurosci. Lett. 2011, 488:60-64.
102. Halliwell B., Gutteridge J.M.C. Free radicals in biology and medicine 2008, Oxford University Press, USA. 3rd ed.
103. Vaishnav R.A., Singh I.N., Miller D.M., Hall E.D. Lipid peroxidation-derived reactive aldehydes directly and differentially impair spinal cord and brain mitochondrial function. J. Neurotrauma 2010, 27:1311-1320.
104. Althaus J.S., Oien T.T., Fici G.J., Scherch H.M., Sethy V.H., VonVoigtlander P.F. Structure activity relationships of peroxynitrite scavengers an approach to nitric oxide neurotoxicity. Res. Commun. Chem. Pathol. Pharmacol. 1994, 83:243-254.
105. Singh I.N., Sullivan P.G., Hall E.D. Peroxynitrite-mediated oxidative damage to brain mitochondria: protective effects of peroxynitrite scavengers. J. Neurosci. Res. 2007, 85:2216-2223.
106. Hall E.D., Kupina N.C., Althaus J.S. Peroxynitrite scavengers for the acute treatment of traumatic brain injury. Ann. N. Y. Acad. Sci. 1999, 890:462-468.
107. Hamann K., Nehrt G., Ouyang H., Duerstock B., Shi R. Hydralazine inhibits compression and acrolein-mediated injuries in ex vivo spinal cord. J. Neurochem. 2008, 104:708-718.
108. Hamann K., Shi R. Acrolein scavenging: a potential novel mechanism of attenuating oxidative stress following spinal cord injury. J. Neurochem. 2009, 111:1348-1356.
109. Galvani S., Coatrieux C., Elbaz M., Grazide M.H., Thiers J.C., Parini A., Uchida K., Kamar N., Rostaing L., Baltas M., Salvayre R., Negre-Salvayre A. Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives. Free Radic. Biol. Med. 2008, 45:1457-1467.
110. Wilcox C.S. Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol. Ther. 2010, 126:119-145.
111. Carroll R.T., Galatsis P., Borosky S., Kopec K.K., Kumar V., Althaus J.S., Hall E.D. 4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (Tempol) inhibits peroxynitrite-mediated phenol nitration. Chem. Res. Toxicol. 2000, 13:294-300.
112. Krishna M.C., DeGraff W., Hankovszky O.H., Sar C.P., Kalai T., Jeko J., Russo A., Mitchell J.B., Hideg K. Studies of structure-activity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage. J. Med. Chem. 1998, 41:3477-3492.
113. Deng-Bryant Y., Singh I.N., Carrico K.M., Hall E.D. Neuroprotective effects of tempol, a catalytic scavenger of peroxynitrite-derived free radicals, in a mouse traumatic brain injury model. J. Cereb. Blood Flow Metab. 2008, 28:1114-1126.
114. Zhang R., Shohami E., Beit-Yannai E., Bass R., Trembovler V., Samuni A. Mechanism of brain protection by nitroxide radicals in experimental model of closed-head injury. Free Radic. Biol. Med. 1998, 24:332-340.
115. Xiong Y., Singh I.N., Hall E.D. Tempol protection of spinal cord mitochondria from peroxynitrite-induced oxidative damage. Free. Radic. Res. 2009, 43:604-612.
116. Hillard V.H., Peng H., Zhang Y., Das K., Murali R., Etlinger J.D., Zeman R.J. Tempol, a nitroxide antioxidant, improves locomotor and histological outcomes after spinal cord contusion in rats. J. Neurotrauma 2004, 21:1405-1414.
117. Pervaiz S., Holme A.L. Resveratrol: its biologic targets and functional activity. Antioxid. Redox Signal 2009, 11:2851-2897.
118. Kiziltepe U., Turan N.N., Han U., Ulus A.T., Akar F. Resveratrol, a red wine polyphenol, protects spinal cord from ischemia-reperfusion injury. J. Vasc. Surg. 2004, 40:138-145.
119. Yang Y.B., Piao Y.J. Effects of resveratrol on secondary damages after acute spinal cord injury in rats. Acta. Pharmacol. Sin. 2003, 24:703-710.
120. Ates O., Cayli S., Altinoz E., Gurses I., Yucel N., Kocak A., Yologlu S., Turkoz Y. Effects of resveratrol and methylprednisolone on biochemical, neurobehavioral and histopathological recovery after experimental spinal cord injury. Acta. Pharmacol. Sin. 2006, 27:1317-1325.
121. Liu C., Shi Z., Fan L., Zhang C., Wang K., Wang B. Resveratrol improves neuron protection and functional recovery in rat model of spinal cord injury. Brain Res. 2011, 1374:100-109.
122. Ates O., Cayli S., Altinoz E., Gurses I., Yucel N., Sener M., Kocak A., Yologlu S. Neuroprotection by resveratrol against traumatic brain injury in rats. Mol. Cell. Biochem. 2007, 294:137-144.
123. Sonmez U., Sonmez A., Erbil G., Tekmen I., Baykara B. Neuroprotective effects of resveratrol against traumatic brain injury in immature rats. Neurosci. Lett. 2007, 420:133-137.
124. Zhang D.D. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev. 2006, 38:769-789.
125. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47:89-116.
126. Shih A.Y., Johnson D.A., Wong G., Kraft A.D., Jiang L., Erb H., Johnson J.A., Murphy T.H. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J. Neurosci. 2003, 23:3394-3406.
127. Mao L., Wang H., Qiao L., Wang X. Disruption of Nrf2 enhances the upregulation of nuclear factor-kappaB activity, tumor necrosis factor-alpha, and matrix metalloproteinase-9 after spinal cord injury in mice. Mediators Inflamm. 2010, 2010:238-321.
128. Mao L., Wang H., Wang X., Liao H., Zhao X. Transcription factor nrf2 protects the spinal cord from inflammation produced by spinal cord injury. J. Surg. Res. 2011, 170:e105-e115.
129. Wang X., De Rivero Vaccari J.P., Wang H., Diaz P., German R., Marcillo A., Keane R.W. Activation of the nuclear factor E2-related factor 2/antioxidant response element pathway is neuroprotective following spinal cord injury. J. Neurotrauma 2011, 10.1089/neu.2011.1922.
130. Yan W., Wang H.D., Hu Z.G., Wang Q.F., Yin H.X. Activation of Nrf2-ARE pathway in brain after traumatic brain injury. Neurosci. Lett. 2008, 431:150-154.
131. Hong Y., Yan W., Chen S., Sun C.R., Zhang J.M. The role of Nrf2 signaling in the regulation of antioxidants and detoxifying enzymes after traumatic brain injury in rats and mice. Acta. Pharmacol. Sin. 2010, 31:1421-1430.
132. Dash P.K., Zhao J., Orsi S.A., Zhang M., Moore A.N. Sulforaphane improves cognitive function administered following traumatic brain injury. Neurosci. Lett. 2009, 460:103-107.
133. Chen G., Fang Q., Zhang J., Zhou D., Wang Z. Role of the Nrf2-ARE pathway in early brain injury after experimental subarachnoid hemorrhage. J. Neurosci. Res. 2011, 89:515-523.
134. Jin W., Kong J., Wang H., Wu J., Lu T., Jiang J., Ni H., Liang W. Protective effect of tert-butylhydroquinone on cerebral inflammatory response following traumatic brain injury in mice. Injury 2011, 42:714-718.
135. Singh I.N., Sullivan P.G., Deng Y., Mbye L.H., Hall E.D. Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy. J. Cereb. Blood Flow Metab. 2006, 26:1407-1418.
136. Thompson S.N., Gibson T.R., Thompson B.M., Deng Y., Hall E.D. Relationship of calpain-mediated proteolysis to the expression of axonal and synaptic plasticity markers following traumatic brain injury in mice. Exp. Neurol. 2006, 201:253-265.